Medical Laboratories & Research

(DGX) Quest Diagnostics Downgraded to Underperform

On Feb 1, we downgraded Quest Diagnostics (DGX), a leading player in the diagnostic testing market, to Underperform based on the company’s dismal fourth-quarter 2012 results as well as a disappointing outlook for first quarter 2013.

Why...

11Feb2013 | | Comments Off on (DGX) Quest Diagnostics Downgraded to Underperform | Continued

(DGX) Quest Diagnostics Remains Neutral

We recently reiterated our Neutral recommendation on Quest Diagnostics (DGX), the leading providers of commercial laboratory services in North America, with a target price of $61.00.

The company...

4Dec2012 | | Comments Off on (DGX) Quest Diagnostics Remains Neutral | Continued

(DGX) Quest Diagnostics Disappoints in Third Quarter – Guides Low

Leading diagnostic testing company Quest Diagnostics (DGX) reported earnings per share (EPS) of $1.01 in the third quarter of 2012, down considerably from $1.08 in the year-ago period. However, after taking into account certain charges...

29Oct2012 | | Comments Off on (DGX) Quest Diagnostics Disappoints in Third Quarter – Guides Low | Continued

(GHDX) Genomic Health: A Strong Buy

Consistent uptrend in Oncotype sales, pipeline development, strategic investments and impressive second quarter performance have helped Genomic Health (GHDX), a global cancer company, to achieve a Zacks #1 Rank (Strong Buy) on October...

23Oct2012 | | Comments Off on (GHDX) Genomic Health: A Strong Buy | Continued

(DGX) Quest Diagnostics’ Simplexa Passes FDA Test

Quest Diagnostics (DGX), a prominent player in the field of diagnostic testing, recently received the U.S. Food and Drug Administration’s (“FDA”) 510(k) clearance for its Simplexa Flu A/B & RSV Direct test, which was developed...

23Oct2012 | | Comments Off on (DGX) Quest Diagnostics’ Simplexa Passes FDA Test | Continued

(LH) Laboratory Corporation of America Holdings Prices Senior Notes

Laboratory Corporation of America Holdings (LH), has priced its senior notes to be used primarily to repay certain amounts outstanding under its existing credit facility (announced in December, 2011), for an aggregate purchase price...

30Aug2012 | | Comments Off on (LH) Laboratory Corporation of America Holdings Prices Senior Notes | Continued

(LH) Laboratory Corporation of America Holdings Earnings Scorecard

Laboratory Corporation of America Holdings’ (LH) disappointing second quarter 2012 results, released on July 19, prompted analysts to slash their estimates for the forthcoming periods, pricing in the challenges currently at play in...

31Jul2012 | | Comments Off on (LH) Laboratory Corporation of America Holdings Earnings Scorecard | Continued

(LH) Laboratory Corporation of America Holdings Earnings Preview

Laboratory Corporation of America Holdings (LH) is scheduled to release its second quarter fiscal 2012 earnings on Thursday, July 19, 2012, before the market opens. The company is expected to report earnings per share (EPS) of $1.78...

23Jul2012 | | Comments Off on (LH) Laboratory Corporation of America Holdings Earnings Preview | Continued

(LH) Laboratory Corporation of America Holdings-Orchid Deal Evinces FTC Nod

Laboratory Corporation of America Holdings (LH) received the much awaited nod from the US Federal Trade Commission (FTC) for the proposed acquisition of Orchid Cellmark (ORCH)....

9Dec2011 | | 0 comments | Continued

(LH) Laboratory Corporation of America Holdings Extends Orchid Bid Again

Laboratory Corporation of America Holdings (LH) has once again extended the tender offer for Orchid Cellmark (ORCH) until December 9, 2011. The company had earlier...

7Dec2011 | | 0 comments | Continued

(PPDI) Pharmaceutical Product Development Shareholders Nod to Merger

Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that its shareholders have approved the merger with privately held firms The Carlyle Group and Hellman & Friedman. The merger...

6Dec2011 | | 0 comments | Continued

(GHDX) Genomic Health to Showcase Key Data

Genomic Health (GHDX), an oncology based biotech company, will present results from 16 studies at the San Antonio Breast Cancer Symposium in December. The company has been recording robust revenue growth over the last few quarters...

1Dec2011 | | 0 comments | Continued

(LH) Laboratory Corporation of America Holdings Earnings Scorecard

The announcement of Laboratory Corporation of America Holdings’ (LH) third quarter fiscal 2011 results, as on October 20, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011.

Third...

3Nov2011 | | 0 comments | Continued

(PPDI) Pharmaceutical Product Development to Go Private

Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that it has entered into an agreement to be acquired by privately held The Carlyle Group and Hellman & Friedman for $3.9 billion...

11Oct2011 | | 0 comments | Continued

(PPDI) Pharmaceutical Product Development Hires New CEO

Pharmaceutical Product Development, Inc. (PPDI) recently announced the appointment of Mr. Raymond Hill as its new Chief Executive Officer (CEO) and also a member of the Board of Directors effective from September 16. Raymond Hill...

24Sep2011 | | 0 comments | Continued

(LH) Laboratory Corporation of America Holdings-UnitedHealth Extend Pact

Last week, Laboratory Corporation of America Holdings (LH) announced that it has extended its agreement with UnitedHealthcare Insurance Company, an affiliate of UnitedHealth Group (UNH)....

15Sep2011 | | 0 comments | Continued

(DGX) Quest Diagnostics Seeks Regular Colon Test

Leading diagnostics player Quest Diagnostics (DGX) is dissatisfied with the outcome of a nationwide study that it had carried out along with the Colon Cancer Alliance. The data demonstrated that one in three of men and women aged 60-70...

29Jun2011 | | 0 comments | Continued

(DGX) Quest Diagnostics Launches Gazelle on Android

Quest Diagnostics (DGX),a leading player in the diagnostic testing market, recently launched a new version of its mobile health platform, Gazelle. The company claims that this latest version will work in sync with Google’s...

23Jun2011 | | 0 comments | Continued

(LH) Laboratory Corporation of America Holdings Extends Orchid Tender Offer

Laboratory Corporation of America Holdings (LH) has decided to extend the tender offer for Orchid Cellmark (ORCH) till July 15, 2011. Earlier, in May 2011, the company...

19Jun2011 | | 0 comments | Continued

(PPDI) Pharmaceutical Product Development Misses Estimates by a Penny

Pharmaceutical Product Development, Inc. (PPDI) reported first quarter 2011 earnings of 32 cents per share, above the year-ago earnings of 14 cents per share. Earnings growth was driven by higher revenue, improved gross margins and...

3May2011 | | 0 comments | Continued

(DGX) Quest Diagnostics Expedites Celera Acquisition

Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced...

15Apr2011 | | 0 comments | Continued

(DGX) Quest Diagnostics – Bear of the Day

Quest Diagnostics (DGX) second-quarter EPS of $0.89 beats the Zacks Consensus Estimate by a penny and the year-ago quarters by 7 cents. However, revenues declined 1.4% to
$1.9 billion, driven by a decline in both volume and pricing.

Meanwhile,...

2Aug2010 | | 0 comments | Continued

(GHDX) Genomic Heath Incorporated – Bear of the Day

Genomic Health’s (GHDX) first quarter 2010 loss of $0.07 per share missed the Zacks Consensus Estimate of a loss of $0.03. Although the company’s lead product, Oncotype DX breast cancer test, recorded a year-over-year...

23Jul2010 | | 0 comments | Continued

(LH) LabCorp First Quarter 2010 Earnings Scorecard

First Quarter Highlights

On April 21, LabCorp (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared with earnings of $1.22 in the year-ago period. However, after considering restructuring...

23May2010 | | 0 comments | Continued

(GHDX) Genomic Health’s Loss Wider Than Expected

Genomic Health Inc’s (GHDX) first quarter 2010 loss of 7 cents per share was wider than the Zacks Consensus Estimate of a net loss of 3 cents. The company had suffered a loss of 16 cents in the prior-year period.

Total revenues...

6May2010 | | 0 comments | Continued

(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer

Recently, Array BioPharma Inc. (ARRY) struck a deal with Novartis AG (NVS) to develop its small-molecule methyl ethyl ketone (MEK) inhibitors for treating cancer.

The...

22Apr2010 | | 0 comments | Continued

(LH) Laboratory Corporation of America Holdings Misses by a Penny

Laboratory Corporation of America Holdings (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared to earnings of $1.22 reported in the year-ago period. However, after considering restructuring and other special...

22Apr2010 | | 0 comments | Continued

(DGX) Quest Diagnostics Beats Expectations but Revenues are Unchanged

Quest Diagnostics (DGX) reported first quarter fiscal 2010 earnings per share (EPS) of 89 cents, unchanged from the year-ago period. However, excluding the impact of severe weather conditions and charges associated with workforce reduction...

21Apr2010 | | 0 comments | Continued

(GHDX) Genomic Health Announces New Distribution Deal

Recently, Genomic Health, Inc. (GHDX) announced that it has agreed to distribute its breast cancer assay Oncotype DX with Palex Medical S.A. in Spain and Portugal. The company also announced encouraging data on Oncotype DX at the...

29Mar2010 | | 0 comments | Continued

(BRLI) Bio-Reference Labs – Analysts React By Raising Estimates

Bio-Reference Labs (BRLI) recently beat earnings estimates once again. Shares are up roughly 10% since being featured as a Zacks Rank Buy in December.

Company Description

Bio-Reference Laboratories,...

29Mar2010 | | 0 comments | Continued